BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11447230)

  • 1. Serine 132 is the C3 covalent attachment point on the CH1 domain of human IgG1.
    Vidarte L; Pastor C; Mas S; Blázquez AB; de los Rios V; Guerrero R; Vivanco F
    J Biol Chem; 2001 Oct; 276(41):38217-23. PubMed ID: 11447230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small domain (6.5 kDa) of bacterial protein G inhibits C3 covalent binding to the Fc region of IgG immune complexes.
    Muñoz E; Vidarte L; Pastor C; Casado M; Vivanco F
    Eur J Immunol; 1998 Aug; 28(8):2591-7. PubMed ID: 9710236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The covalent interaction of C3 with IgG immune complexes.
    Vivanco F; Muñoz E; Vidarte L; Pastor C
    Mol Immunol; 1999; 36(13-14):843-52. PubMed ID: 10698338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3.
    Muñoz E; Vidarte L; Casado MT; Pastor C; Vivanco F
    Int Immunol; 1998 Feb; 10(2):97-106. PubMed ID: 9580208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent attachment of human complement C3 to IgG. Identification of the amino acid residue involved in ester linkage formation.
    Sahu A; Pangburn MK
    J Biol Chem; 1994 Nov; 269(46):28997-9002. PubMed ID: 7961863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a major binding site for complement C3 on the IgG1 heavy chain.
    Shohet JM; Pemberton P; Carroll MC
    J Biol Chem; 1993 Mar; 268(8):5866-71. PubMed ID: 8449952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.
    Antón LC; Alcolea JM; Sánchez-Corral P; Marqués G; Sánchez A; Vivanco F
    Biochem J; 1989 Feb; 257(3):831-8. PubMed ID: 2784671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
    Takata Y; Tamura N; Fujita T
    J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How immune complexes from certain IgG NAbs and any F(ab')₂ can mediate excessive complement activation.
    Lutz HU
    Adv Exp Med Biol; 2012; 750():186-96. PubMed ID: 22903675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
    Gadd KJ; Reid KB
    Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localization of the human complement component C3 binding site on the IgG heavy chain.
    Shohet JM; Bergamaschini L; Davis AE; Carroll MC
    J Biol Chem; 1991 Oct; 266(28):18520-4. PubMed ID: 1917974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
    Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes.
    Edberg JC; Tosic L; Wright EL; Sutherland WM; Taylor RP
    J Immunol; 1988 Dec; 141(12):4258-65. PubMed ID: 3198918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3b2-IgG complexes retain dimeric C3 fragments at all levels of inactivation.
    Jelezarova E; Luginbuehl A; Lutz HU
    J Biol Chem; 2003 Dec; 278(51):51806-12. PubMed ID: 14527961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of C3 and C3b with immunoglobulin G.
    Kulics J; Rajnavölgyi E; Füst G; Gergely J
    Mol Immunol; 1983 Aug; 20(8):805-10. PubMed ID: 6621540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism.
    Theofilopoulos AN; Dixon FJ; Bokisch VA
    J Exp Med; 1974 Oct; 140(4):877-94. PubMed ID: 4139225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covalent binding of C3b to monoclonal antibodies selectively up-regulates heavy chain epitope recognition by T cells.
    Santoro L; Drouet C; Reboul A; Mach JP; Colomb MG
    Eur J Immunol; 1994 Jul; 24(7):1620-6. PubMed ID: 8026522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breakdown of C3 covalently bound to F(ab')2 immune complexes after complement activation by the alternative pathway.
    Antón LC; Alcolea JM; Marqués G; Sánchez-Corral P; Vivanco F
    Complement; 1986; 3(2):53-62. PubMed ID: 3769463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor B.
    Hinshelwood J; Spencer DI; Edwards YJ; Perkins SJ
    J Mol Biol; 1999 Nov; 294(2):587-99. PubMed ID: 10610782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.